Clinical trials: Sjögren's Syndrome
Primary Sjögren's Syndrome
Acupuncture Combined With Hydroxychloroquine
To observe the clinical efficacy of acupuncture combined with hydroxychloroquine sulfate tablets on the symptoms of dry mouth and dry eyes in primary Sjögren's syndrome.
- Trial name
- NCT06432101
- Testing
- Acupuncture combined with oral hydroxychloroquine sulfate tablets
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Senyue Zhang
Primary Sjögren's Syndrome
A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome
Primary Sjögren's Syndrome (pSS) is an autoimmune disorder characterized by keratoconjunctivitis sicca and xerostomia. In addition, various extraglandular manifestations may develop.
- Trial name
- NCT02464319
- Testing
- hrIL-2 active
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University People's Hospital
Primary Sjögren's Syndrome
Reliability, Validity of the Turkish Version of the Primary Sjögren Syndrome Quality of Life (PSS-QoL) Questionnaire
The purpose of this study was to investigate adaptation, validity, and reliability of the Turkish version of the Primary Sjögren's Syndrome Quality of Life (PSS-QoL) Questionnaire
- Trial name
- NCT04858464
- Testing
- Survey study
- Where
- Turkey (Türkiye)
- Volunteers
- 75 people
- Sponsor
- Gazi University
Sjogren Syndrome
"Validity and Reliability of Pelvic Floor Distress Inventory-20 in Primary Sjögren's Syndrome"
The aim of this study is to examine the Turkish validity and reliability of the Pelvic Floor Distress Inventory-20 in patients with pSS.
- Trial name
- NCT07248436
- Testing
- the validity and reliability study
- Where
- Turkey (Türkiye)
- Volunteers
- 10 people
- Sponsor
- Pamukkale University
Autoimmune Diseases
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Proof of Mechanism of GSK2618960 in Primary Sjögren's Syndrome (pSS)
This study aims to evaluate the safety, tolerability and PK of repeat dose administration of GSK2618960 in the treatment of pSS.
- Trial name
- NCT03239600
- Testing
- GSK2618960 2 mg/kg, Methotrexate
- Where
- United Kingdom
- Sponsor
- GlaxoSmithKline
Primary Sjögren's Syndrome Painful Sensory Neuropathies
Intravenous Immunoglobulins for the Treatment of Primary Sjögren's Syndrome Associated Painful Sensory Neuropathies
To summarise, the peripheral neurological complications experienced by patients with primary Sjögren's syndrome are particularly bothersome since they are common and often result in significant disability related to pain or motor…
- Trial name
- TINISS (NCT03700138)
- Testing
- Privigen® 100mg/ml at the dose of 2g/kg of body weight, NaCl 0,9%
- Where
- France
- Volunteers
- 24 people
- Sponsor
- University Hospital, Strasbourg, France
Primary Gougerot-Sjögren Syndrome, Systemic Sclerosis, Diffuse
Quantification and Characterization of Circulating Epithelial and Endothelial Cells in Gougerot-Sjögren Syndrome, Compared to Systemic Sclerosis
Primary Gougerot-Sjögren's syndrome is a systemic autoimmune disease belonging to the group of connectivities, whose physiopathology remains largely unknown.
- Trial name
- CIRCEE (NCT05528809)
- Testing
- Blood sampling
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Montpellier
Sjögren's Syndrome, Meibomian Gland Dysfunction
Is Sjögren's Syndrome Associated With Meibomian Gland Dysfunction ?
The investigators hypothesize that the dry eye caused by SS may include the evaporative type, resulting from the MGD. Furthermore, the investigators hypothesize that both pSS and sSS are associated with MGD.To test our…
- Trial name
- NCT03060005
- Testing
- Tears Naturale Forte, liposic
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Tung Wah Hospital
Sjogren's Syndrome With Dry Eye
RHPRG4 FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE
A 1-day, randomized (1:1) controlled, masked, pre-market study. Subjects with moderate to severe Sjögren's related Dry Eye Disease will be evaluated at 0, 5, 30 \& 90 minutes post dose of either rhPRG4 (Treatment group) or…
- Trial name
- NCT06520202
- Testing
- rhPRG4 (450 µg/mL), Vehicle
- Where
- Australia
- Volunteers
- 8 people
- Sponsor
- Lubris Bio Pty Ltd
Primary Sjögren's Syndrome
Hydroxychloroquine Versus Placebo in Primary Sjögren's Syndrome
Primary Sjögren's syndrome (SJp) affects 0.1% of the population. This systemic autoimmune disease systemic is characterized by disabling dryness, fatigue and pain, and systemic complications in 30% of patients.
- Trial name
- JOQUER (NCT00632866)
- Testing
- Hydroxychloroquine
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Primary Sjögren Syndrome
Vaccine Coverage and Primary Sjögren'Syndrome
Evaluation of vaccination coverage for influenza, pneumococcus and DTP in patients with pSS and investigated the reasons for non-vaccination.
- Trial name
- VACGREN (NCT04224454)
- Testing
- Questionnaire
- Where
- France
- Volunteers
- 111 people
- Sponsor
- University Hospital, Montpellier
Primary Sjögren's Syndrome
The Efficacy and Safety of Iguratimod (IGU) in the Treatment of Primary Sjögren's Syndrome
A multi-center, prospective, open-label, randomized controlled study of efficacy and safety of Iguratimod in patients with Primary Sjögren's syndrome
- Trial name
- NCT04981145
- Testing
- Iguratimod Tablets, Hydroxychloroquine Sulfate Tablets
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Sjogren's Syndrome, Xerostomia
Diagnostic Interest of the Buccal Schirmer Test in Xerostomia During Sjögren's Syndrome: XERODIAG
Xerostomia is a common and very bothersome manifestation that impairs the quality of life in Sjogren's syndrome. Its diagnosis mainly relies on the measurement of salivary flow (SF).
- Conditions
- Sjogren's Syndrome, Xerostomia, Diagnosis
- Trial name
- XERODIAG (NCT06530940)
- Testing
- Buccal Schirmer Test
- Volunteers
- 180 people
- Sponsor
- University Tunis El Manar
Sjogren's Syndrome
EVADRY® in the Treatment of Xerostomia in Sjögren's Syndrome
Xerostomia is a common and very bothersome manifestation that impairs the quality of life in Sjogren's syndrome. Symptomatic therapeutic alternatives for this syndrome are limited in Tunisia.
- Trial name
- DRYLESS (NCT06313905)
- Testing
- EVADRY
- Volunteers
- 180 people
- Sponsor
- University Tunis El Manar
Sjogren's Disease, Fatigue
Explanatory Factors and Predictors of Fatigue in Patients With Sjögren's Disease: A 3-month Longitudinal Study
This prospective longitudinal study will be conducted in patients diagnosed with Sjögren's disease who are followed at the rheumatology outpatient clinic of Kahramanmaras Sutcu Imam University Medical Faculty Hospital.
- Trial name
- NCT07544394
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Kahramanmaras Sutcu Imam University
Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye
Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease
The goal of this research is to determine if the Tangible Boost system adequately replenishes the Hydra-PEG coating on the surface of a rigid contact lens.
- Conditions
- Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye, Sjogren's Syndrome, Dry Eye
- Trial name
- NCT04313725
- Testing
- Tangible Boost
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Tangible Science
Primary Sjögren's Syndrome (pSS)
CM336 for Active Sjogren's Syndrome Study
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CM336 in adult participants with active primary Sjogren's Syndrome.
- Trial name
- NCT07642843
- Testing
- CM336
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Keymed Biosciences Co.Ltd
Sjögren's Disease
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
To evaluate efficacy, safety, and tolerability of DDY391 up to 52 weeks in participants with Sjögren's disease (SjD) and to determine the dose response relationship of DDY391 in participants with SjD, to support dose selection…
- Trial name
- NCT07737743
- Testing
- DDY391
- Where
- 25 sites in United States, Australia and 4 more
- Volunteers
- 344 people
- Sponsor
- Novartis Pharmaceuticals
Sjögren's Syndrome, Xerostomia
The Effect of Chewing Gum, Exercises of the Tongue, Lip, Jaw on Salivation, Xerostomia, Dysphagia in Sjögren's Syndrome
Sjögren's syndrome (SS) is a chronic, systemic and autoimmune disease characterized by inflammation, fibrosis and dysfunction of exocrine glands such as tear and salivary glands.
- Conditions
- Sjögren's Syndrome, Xerostomia, Dysphagia, Salivary Flow Rate
- Trial name
- SS (NCT05680064)
- Testing
- Tongue, lip, chin exercise group
- Where
- Turkey (Türkiye)
- Volunteers
- 86 people
- Sponsor
- Saglik Bilimleri Universitesi
Primary Sjögren's Syndrome
The ASSESS National Multi-center Prospective Cohort
The ASSESS national multi-center prospective cohort (Assessment of Systemic complications (Signs) and Evolution in Sjögren's Syndrome "SS") was set up in 2006 thanks to a grant of the French Ministry of Health.
- Trial name
- ASSESS (NCT03040583)
- Testing
- No intervention
- Where
- France
- Volunteers
- 395 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris